InMed Pharmaceuticals (INM) EBIT (2021 - 2026)

InMed Pharmaceuticals has reported EBIT for 6 years, with the latest figure at -$2.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 46.32% year-over-year to -$2.8 million; the trailing twelve-month figure through Mar 2026 stood at -$9.2 million (down 15.78% YoY), and the FY2025 full-year result was -$7.9 million, up 3.05% from the prior year.
• EBIT for Q1 2026 stood at -$2.8 million, down from -$2.1 million in the prior quarter.
• The five-year high for EBIT was -$485150.0 in Q2 2023, with the low at -$6.5 million in Q2 2022.
• Historically, EBIT has averaged -$2.5 million across 5 years, with a median of -$2.2 million in 2023.
• Annual changes were most pronounced in 2023 — EBIT soared 92.56% — and 2024, when it slumped 319.3%.
• InMed Pharmaceuticals' EBIT stood at -$2.2 million in 2022, then increased by 25.7% to -$1.6 million in 2023, then slumped by 37.03% to -$2.3 million in 2024, then grew by 6.72% to -$2.1 million in 2025, then slumped by 32.78% to -$2.8 million in 2026.
• The last three EBIT figures came in at -$2.8 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.